Add to ORKGUntil HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese experiences should provide new information for the treatment of chronic hepatitis C. Keywords: Direct-acting antiviral agents (DAA), HCV, pegylated interferon, ribavirin, standard of care (SOC )
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virolo...
Hepatitis C contagion is one of the primary causes of hepatitis C disease in the Flaviviridae family...
The current standard treatment for hepatitis C virus (HCV) infection is a combination of pegylated i...
Chronically hepatitis C virus (HCV) infects about 180 million people worldwide and it is a major cau...
The goal of antiviral therapy for patients with chronic hepa-titis C virus (HCV) infection is to att...
Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic bl...
Combination therapy with pegylated interferon alfa (PEG-IFN alfa) and the nucleoside analogue ribavi...
Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of genot...
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and markete...
With the release of new oral direct-acting antiviral agents (DAAs), the interferon (IFN)-free treatm...
Chronic hepatitis C is a major worldwide health problem with an estimated prevalence of 1.6-2%. The ...
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now availabl...
Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is eff...
The combination of pegylated interferon (PEG-IFN) and riba-virin (RBV), the current therapy for hepa...
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virolo...
Hepatitis C contagion is one of the primary causes of hepatitis C disease in the Flaviviridae family...
The current standard treatment for hepatitis C virus (HCV) infection is a combination of pegylated i...
Chronically hepatitis C virus (HCV) infects about 180 million people worldwide and it is a major cau...
The goal of antiviral therapy for patients with chronic hepa-titis C virus (HCV) infection is to att...
Hepatitis C virus (HCV) affects about 170 million people worldwide and is the most common chronic bl...
Combination therapy with pegylated interferon alfa (PEG-IFN alfa) and the nucleoside analogue ribavi...
Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of genot...
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and markete...
With the release of new oral direct-acting antiviral agents (DAAs), the interferon (IFN)-free treatm...
Chronic hepatitis C is a major worldwide health problem with an estimated prevalence of 1.6-2%. The ...
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now availabl...
Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is eff...
The combination of pegylated interferon (PEG-IFN) and riba-virin (RBV), the current therapy for hepa...
It has been estimated that between 1.5 and 2 million people in Italy have anti-HCV antibodies. The v...
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virolo...
Hepatitis C contagion is one of the primary causes of hepatitis C disease in the Flaviviridae family...